← Back to Clinical Trials
Recruiting NCT02993029

NCT02993029 99Tc-MDP Treatment for Knee Osteoarthritis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02993029
Status Recruiting
Phase
Sponsor Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Condition Treatment Outcome
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2017-09-01
Primary Completion 2027-12-30

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
99Tc-MDPCelecoxib

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2017-09-01 with a primary completion date of 2027-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.

Eligibility Criteria

Inclusion Criteria: 1. Participants with painful osteoarthritis; 2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan; 3. Participants voluntarily participate in the trial, and signed the informed consent. Exclusion Criteria: 1. Knee joint replacement; 2. Inflammatory arthritis or joint infection of knee; 3. Nervous joint disease; 4. Fracture of joint; 5. Gout arthritis of the knee; 6. Traumatic arthritis.

Contact & Investigator

Central Contact

Chao Ma, MD

✉ mc_7419@hotmail.com

📞 +86-021-25078593

Principal Investigator

Zhongwei Lv, MD

PRINCIPAL INVESTIGATOR

The 10th Hospital, Tongji University

Frequently Asked Questions

Who can join the NCT02993029 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Treatment Outcome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02993029 currently recruiting?

Yes, NCT02993029 is actively recruiting participants. Contact the research team at mc_7419@hotmail.com for enrollment information.

Where is the NCT02993029 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT02993029 clinical trial?

NCT02993029 is sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. The principal investigator is Zhongwei Lv, MD at The 10th Hospital, Tongji University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology